Last year, Halozyme Therapeutics Inc generated 867.84M USD for its biggest-performing segment, Royalties. The United States made the largest contribution, accounting for 822.98M USD last year.
By Business
Revenue
Proportion
Annual
Annual
Quarterly
Royalties
Sales of proprietary products
Sales of bulk rHuPH20
Sales-based milestones
Sales of device partnered products
Event-based development and regulatory milestones and other fees
Upfront license fees
Device Licensing and development revenue
ENHANZE
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Royalties
867.84M(62.14%)
570.99M(56.24%)
447.87M(54.01%)
360.48M(54.61%)
203.90M(45.99%)
88.60M(33.11%)
69.90M(35.66%)
Sales of proprietary products
194.61M(13.93%)
166.62M(16.41%)
130.83M(15.78%)
72.85M(11.04%)
23.26M(5.25%)
17.03M(6.36%)
17.00M(8.67%)
Sales of bulk rHuPH20
133.02M(9.52%)
86.33M(8.50%)
115.44M(13.92%)
82.08M(12.43%)
80.96M(18.26%)
38.24M(14.29%)
48.28M(24.64%)
Sales-based milestones
70.00M(5.01%)
30.00M(2.95%)
--(--)
10.00M(1.51%)
50.00M(11.28%)
15.00M(5.61%)
--(--)
Sales of device partnered products
48.81M(3.50%)
50.54M(4.98%)
54.58M(6.58%)
36.10M(5.47%)
--(--)
--(--)
--(--)
Event-based development and regulatory milestones and other fees